CAPL Earnings

CAPL reported its earnings on 2026-02-25, showcasing a revenue of against an estimate of 748.01M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.05 by 0%. The stock experienced a 2.48% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CAPL's earnings announcement on 2026-02-25, the stock price moved by 2.48% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, CAPL's stock price tends to shift by an average of 4.69% in the 10 days leading up to earnings and 1.07% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate CAPL's annual revenue to reach 708.24M, while the EPS is projected at -0.17. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CAPL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CAPL's stock price typically moves by 4.69% in the 10 days before its earnings and 1.07% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.17 and revenue of 708.24M.

The earnings call reflects mixed financial performance with a net loss of $7.1 million, declining wholesale volumes, and increased operating expenses. Although adjusted EBITDA improved slightly, distributable cash flow decreased, and distribution coverage weakened. The Q&A section highlighted challenges such as subdued demand and weather impacts, with management providing vague responses on tariff impacts. The absence of strong positive catalysts and weak financial health indicators suggest a negative stock price reaction, likely in the range of -2% to -8%.